source
- Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory marketAnalysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
- Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trialErasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…